臨床外科74巻8号

2019年08月発行

特集 これだけは押さえたい！—大腸癌取扱い規約・治療ガイドライン—改訂のポイント

大腸癌治療ガイドライン2019

外科医が行う補助化学療法

著者： 岡﨑聡¹ 石川敏昭¹ 植竹宏之¹

所属機関： ¹東京医科歯科大学大学院総合外科学

ページ範囲：P.972 - P.977

文献概要

【ポイント】
◆オキサリプラチン（OX）併用療法は，最も再発抑制・予後改善効果の高いレジメンある．
◆OXによる末梢神経障害の出現頻度は用量依存的に増加し，補助療法終了3年後も約20%の症例で症状が残存する．
◆再発高リスクでは6か月のOX併用療法が推奨され，再発低リスクでは3か月のCAPOX療法か6か月のFP単独療法がオプションとなる．

参考文献

1）André T, Boni C, Navarro M, et al：Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage Ⅱ or Ⅲ colon cancer in the MOSAIC trial. J Clin Oncol 27：3109-3116, 2009

2）Schmoll HJ, Tabernero J, Maroun J, et al：Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage Ⅲ Colon Cancer：Final Results of the NO16968 Randomized Controlled Phase Ⅲ Trial. J Clin Oncol 33：3733-3740, 2015

3）de Gramont A, Chibaudel B, Bachet JB, et al：From chemotherapy to targeted therapy in adjuvant treatment for Stage Ⅲ colon cancer. Semin Oncol 38：521-532, 2011

4）McCleary NJ, Meyerhardt JA, Green E, et al：Impact of age on the efficacy of newer adjuvant therapies in patients with stage Ⅱ/Ⅲ colon cancer：findings from the ACCENT database. J Clin Oncol 31：2600-2606, 2013

5）Haller DG, O'Connell MJ, Cartwright TH, et al：Impact of age and medical comorbidity on adjuvant treatment outcomes for Stage Ⅲ colon cancer：a pooled analysis of individual patient data from four randomized, controlled trials. Ann Oncol 26：715-724, 2015

6）Kotaka M, Yoshino T, Oba K, et al：Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage Ⅱ or Ⅲ colon cancer（JFMC41-1001-C2：JOIN trial）. Cancer Chemother Pharmacol 76：75-84, 2015

7）Grothey A, Sobrero AF, Shields AF, et al：Duration of Adjuvant Chemotherapy for Stage Ⅲ Colon Cancer. N Engl J Med 378：1177-1188, 2018

8）Sadahiro S, Tsuchiya T, Sasaki K, et al：Randomized phase Ⅲ trial of treatment duration for oral uracil and tegafur plus leucovorin as adjuvant chemotherapy for patients with stage ⅡB/Ⅲ colon cancer：final results of JFMC33-0502. Ann Oncol 26：2274-2280, 2015

9）Tomita N, Kunieda K, Maeda A, et al：Phase Ⅲ randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with Stage Ⅲ colon cancer：final results of the JFMC37-0801 study. Br J Cancer 120：689-696, 2019

10）Kusumoto T, Ishiguro M, Nakatani E, et al：Updated 5-year survival and exploratory T x N subset analyses of ACTS-CC trial：a randomised controlled trial of S-1 versus tegafur-uracil/leucovorin as adjuvant chemotherapy for Stage Ⅲ colon cancer. ESMO Open 3：e000428, 2018

11）Yamanaka T, Oki E, Yamazaki K, et al：12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage Ⅱ/Ⅲ Colon Cancer With Surgery Alone：The SUNRISE Study. J Clin Oncol 34：2906-2913, 2016